TABLE 3.
Meropenem probabilities of target attainment for different BMI groups, CLCR values, and dosage regimens and methods of administrationa
| Dose (mg) q8h (infusion interval) | BMI group | CLCR (ml/min) | Attainment of PTA for MIC (mg/liter) |
|||||
|---|---|---|---|---|---|---|---|---|
| 0.5 | 1 | 2 | 4 | 8 | 16 | |||
| 500 (II) | Nonobese | 30 | + | + | + | + | − | − |
| 50 | + | + | + | + | − | − | ||
| 150 | − | − | − | − | − | − | ||
| Obese | 30 | + | + | + | + | − | − | |
| 50 | + | + | + | + | − | − | ||
| 150 | − | − | − | − | − | − | ||
| Morbidly obese | 30 | + | + | + | + | − | − | |
| 50 | + | + | + | + | − | − | ||
| 150 | + | − | − | − | − | − | ||
| 500 (PI) | Nonobese | 30 | + | + | + | + | − | − |
| 50 | + | + | + | + | − | − | ||
| 150 | + | + | + | − | − | − | ||
| Obese | 30 | + | + | + | + | − | − | |
| 50 | + | + | + | + | − | − | ||
| 150 | + | + | + | − | − | − | ||
| Morbidly obese | 30 | + | + | + | + | − | − | |
| 50 | + | + | + | + | − | − | ||
| 150 | + | + | + | − | − | − | ||
| 1,000 (II) | Nonobese | 30 | + | + | + | + | + | − |
| 50 | + | + | + | + | + | − | ||
| 150 | − | − | − | − | − | − | ||
| Obese | 30 | + | + | + | + | + | − | |
| 50 | + | + | + | + | + | − | ||
| 150 | + | − | − | − | − | − | ||
| Morbidly obese | 30 | + | + | + | + | + | − | |
| 50 | + | + | + | + | + | − | ||
| 150 | + | + | − | − | − | − | ||
| 1,000 (PI) | Nonobese | 30 | + | + | + | + | + | − |
| 50 | + | + | + | + | + | − | ||
| 150 | + | + | + | + | − | − | ||
| Obese | 30 | + | + | + | + | + | − | |
| 50 | + | + | + | + | + | − | ||
| 150 | + | + | + | + | − | − | ||
| Morbidly obese | 30 | + | + | + | + | + | − | |
| 50 | + | + | + | + | + | − | ||
| 150 | + | + | + | + | − | − | ||
| 2,000 (II) | Nonobese | 30 | + | + | + | + | + | + |
| 50 | + | + | + | + | + | + | ||
| 150 | + | − | − | − | − | − | ||
| Obese | 30 | + | + | + | + | + | + | |
| 50 | + | + | + | + | + | + | ||
| 150 | + | + | − | − | − | − | ||
| Morbidly obese | 30 | + | + | + | + | + | + | |
| 50 | + | + | + | + | + | + | ||
| 150 | + | + | + | − | − | − | ||
| 2,000 (PI) | Nonobese | 30 | + | + | + | + | + | + |
| 50 | + | + | + | + | + | + | ||
| 150 | + | + | + | + | + | − | ||
| Obese | 30 | + | + | + | + | + | + | |
| 50 | + | + | + | + | + | + | ||
| 150 | + | + | + | + | + | − | ||
| Morbidly obese | 30 | + | + | + | + | + | + | |
| 50 | + | + | + | + | + | + | ||
| 150 | + | + | + | + | + | − | ||
a
The target was for the drug concentration to remain above the MIC for 40% of the dosage interval to achieve bactericidal activity. The meropenem target MIC was chosen according to the EUCAST breakpoint (2 mg/liter). BMI, body mass index; q8h, three-times-daily dosing; CLCR, creatinine clearance; II, intermittent infusion; IP, prolonged infusion.